Cargando…
GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?
The glucagon-like peptide-1 (GLP-1) axis has emerged as a major therapeutic target for the treatment of type 2 diabetes. GLP-1 mediates its key insulinotropic effects via a G-protein coupled receptor expressed on β-cells and other pancreatic cell types. The insulinotropic activity of GLP-1 is termin...
Autores principales: | Taing, Meng-Wong, Rose, Felicity J, Whitehead, Jonathan P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051623/ https://www.ncbi.nlm.nih.gov/pubmed/24940046 http://dx.doi.org/10.2147/DDDT.S35723 |
Ejemplares similares
-
Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 Receptor
por: Li, Naichang, et al.
Publicado: (2012) -
GLP-1(28-36)amide, a Long Ignored Peptide Revisited
por: Zhou, Bilan, et al.
Publicado: (2014) -
Cardioprotective effects of GLP‐1(28‐36a): A degraded metabolite or GLP‐1’s better half?
por: Liu, Yangyang, et al.
Publicado: (2020) -
Elevation of Fasting GLP-1 Levels in Child and Adolescent Obesity: Friend or Foe?
por: Kubota, Sodai, et al.
Publicado: (2021) -
Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment
por: Pang, Juan, et al.
Publicado: (2021)